chufangao/CTO huggingface dataset:
Clinical trial NCT02442180: Efficacy and Safety of G-CSF in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid
Official title: Efficacy and Safety of Granulocyte-colony Stimulating Factor in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid: A Randomized, Double-blind, Placebo-controlled, Nationwide Multi-center Study
Acronym: GraCiAH
Sponsor: Chuncheon Sacred Heart Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: failure to recruit eligible patients
Enrollment: 64.0 (ACTUAL)
Number of arms: 4.0
Start date: 2015-07-31
Primary completion date: 2022-07-31
Completion date: 2022-07-31
Plan to share individual participant data: NO
Clinical trial NCT02756611: A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)
Official title: Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)
Acronym: VENICE I
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 258.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-06-22
Primary completion date: 2019-04-10
Completion date: 2022-03-11
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing, please refer to the link below.
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT05253755: Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel
Official title: A Randomized, Observer-Blinded, Within Patient Bilateral Comparison to Study the Safety and Efficacy of Daily Application for 4 Weeks of DBI-001 Gel Versus Aqueous Gel in Subjects With Atopic Dermatitis
Sponsor: DermBiont, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor suspension and not due to safety or site-related matters.
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-06
Primary completion date: 2022-09-09
Completion date: 2022-09-09
Clinical trial NCT04281420: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Official title: A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Acronym: TEACH
Sponsor: Antengene Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Because the sponsor modified the study-product development strategy.
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-13
Primary completion date: 2023-10-02
Completion date: 2023-10-02
Clinical trial NCT04525391: AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer
Official title: Phase II, Single-arm Study of AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer Subjects [SUKSES-N5]
Acronym: SUKSES-N5
Sponsor: Samsung Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Recommended completion of the study due to SUSAR occurring in other clinical trials conducted with the same drug.
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-18
Primary completion date: 2022-01-14
Completion date: 2022-01-14
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02485639: Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination
Official title: Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study was terminated due to CoronaVIrus Disease of 2019 (COVID-19) pandemic.
Enrollment: 27.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-12-23
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Limitations and caveats: Due to the COVID-19 pandemic, all non-essential research was halted at our site (mid-March 2020). New enrollments and follow-up visits were halted, impacting participants' follow-up visits. One Day 28 visit was halted, three Day 90 visits were halted. Seven Day 365 visits were halted. We requested an expansion of the visit windows, however, enrollment for this study ended on March 31, 2020, before research activities could resume at Emory.
Plan to share individual participant data: NO
Clinical trial NCT04672980: RTX-321 Monotherapy in Patients With HPV 16+ Tumors
Official title: A Phase 1 Study of RTX-321 for the Treatment of Patients With Advanced Malignancies Associated With Human Papillomavirus-16 Infection
Sponsor: Rubius Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The Sponsor terminated study after dosing 3 dose groups (9 pts) and closed trial on 11/30/22. RTX-321 was well-tolerated with no DLTs, no related deaths, SAEs or Gr. 3/4 AEs and cleared from circulation rapidly (w/in 10 min).
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-08
Primary completion date: 2022-11-30
Completion date: 2022-11-30
Plan to share individual participant data: NO
Clinical trial NCT03983720: Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?
Official title: Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?
Acronym: FatSEP
Sponsor: Centre Hospitalier Universitaire de Saint Etienne (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: low inclusion rates
Enrollment: 67.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-01-21
Primary completion date: 2021-06-16
Completion date: 2021-07-31
Plan to share individual participant data: NO
Clinical trial NCT04775680: Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma
Official title: A Multicenter, Open-Label, Phase Ib/II Study of ADG106 in Combination With PD-1 Antibody in Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Sponsor: Adagene Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The safety of ADG106 combined with triprilimab has been fully understood.The overall clinical benefit of enrolled subjects was limited and further development of ADG106 was reconsidered.
Enrollment: 25.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-03-11
Primary completion date: 2023-02-09
Completion date: 2023-02-09
Plan to share individual participant data: NO
Clinical trial NCT05926440: Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults
Official title: Phase 3, Multi-center, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of SCB-2023 Vaccine Administered as a Booster Dose to Adults Who Previously Received COVID-19 Vaccine
Sponsor: Clover Biopharmaceuticals AUS Pty Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: we has selected a new candidate vaccine which is monovalent.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-08-17
Primary completion date: 2023-08-17
Completion date: 2023-08-17
Clinical trial NCT04577001: Letrozole in Patients With Hepatopulmonary Syndrome
Official title: Letrozole in Patients With Hepatopulmonary Syndrome: A Double-Blind Randomized Clinical Trial
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low Recruitment Numbers
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-18
Primary completion date: 2021-03-26
Completion date: 2021-03-26
Baseline population: Study terminated due to low recruitment numbers. No subjects were enrolled in the Letrozole group.
Limitations and caveats: Terminated study due to low recruitment numbers.
Plan to share individual participant data: NO
Clinical trial NCT04037891: Topical rVA576 for Treatment of Atopic Keratoconjunctivitis
Official title: Topical rVA576 for Treatment of Atopic Keratoconjunctivitis: a Randomised Placebo-controlled Double Masked Parallel Trial (TRACKER)
Sponsor: AKARI Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The trial has terminated early due to the disruptions caused by the ongoing COVID-19 pandemic. The decision was not related to any efficacy, safety or clinical concerns regarding rVA576/Coversin.
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-20
Primary completion date: 2020-12-15
Completion date: 2020-12-15
Clinical trial NCT02972593: ORthopaedic Trauma Anemia With Conservative Versus Liberal Transfusion
Official title: ORthopaedic Trauma Anemia With Conservative Versus Liberal Transfusion
Acronym: ORACL
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 161.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-03-31
Primary completion date: 2022-06-24
Completion date: 2022-06-24
Baseline population: One hundred patients were enrolled and randomized; however, it was noted the day after enrollment for a patient in the liberal group that the patient should not have been enrolled due to a creatinine higher than allowed by the exclusion criteria. The patient was immediately removed from the study and not included in the statistical analysis.
Limitations and caveats: Significant loss to follow up; Significant resistance by multiple providers at each site to allow conservative treatment algorithm (as most felt liberal was standard of care); Slow enrollment; No funding
Plan to share individual participant data: NO
Clinical trial NCT03278626: Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma
Official title: A Phase I/II Open Label Multi Center Study of Immune Checkpoint Therapy With Nivolumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Sponsor: NYU Langone Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was stopped earlier than anticipated due to slow accrual
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-06-27
Primary completion date: 2019-11-07
Completion date: 2021-05-31
Baseline population: 6 subjects enrolled in Phase 1, and 6 subjects enrolled in Phase 2
Clinical trial NCT04050293: Therapy for Migraine Prevention in Children 6-11 Years of Age
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of SPN-538 as a Therapy for the Prevention of Migraine in Subjects Ages 6-11 Years
Sponsor: Supernus Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Difficulty in recruitment
Enrollment: 26.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-14
Primary completion date: 2024-05-29
Completion date: 2024-05-29
Clinical trial NCT03953326: HeartPhone Cancer Survivors Trial 2019
Official title: Digital Intervention to Promote Physical Activity and Improve Cardiovascular Health Among Cancer Survivors
Sponsor: Penn State University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Futility in recruitment
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-04-23
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT03932318: Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
Official title: A Phase I/II Study of Venetoclax and Azacitidine and Lintuzumab-Ac225 in Patients With Refractory or Relapsed AML
Sponsor: Actinium Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: study postponed
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-03-31
Primary completion date: 2023-12-31
Completion date: 2024-09-30
Clinical trial NCT05457842: A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery
Official title: A Phase 2 Open-label, Dose-finding Study to Determine the Optimal Dose for Lymph Node Visualization Using ASP5354 in Participants With Breast Cancer or Melanoma Undergoing Sentinel Lymph Node Biopsy
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Company's strategic decision
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-08-10
Primary completion date: 2022-09-02
Completion date: 2022-09-20
Baseline population: Full analysis set (FAS): Participant enrolled and received study Investigational product (IP).
Plan to share individual participant data: YES
IPD sharing description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
IPD time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
IPD access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Clinical trial NCT02780583: Treatment of Macrophage Activation Syndrome (MAS) With Anakinra
Official title: Randomized Placebo Controlled Trial of Subcutaneous rhIL-1A (Anakinra) in the Management of Hospitalized Pediatric and Adult Patients With Macrophage Activation Syndrome
Acronym: MAS
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: no further funding to continue, investigator relocated, no replacement found to continue
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-05-15
Primary completion date: 2023-03-31
Completion date: 2024-04-30
Plan to share individual participant data: YES
IPD sharing description: Nurse Study Coordinators will gather and enter data
IPD time frame: Dec 31 2020
IPD access criteria: request to investigator
Clinical trial NCT05179057: Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation
Official title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, With Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation
Sponsor: AlloVir (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study discontinued as DSMB determined it was futile. No safety concerns were noted.
Enrollment: 57.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-04-26
Primary completion date: 2024-01-31
Completion date: 2024-01-31
Limitations and caveats: The study was discontinued following a pre-planned DSMB futility analysis concluding that the study was unlikely to meet its primary endpoint, no safety concerns were identified.
Plan to share individual participant data: NO
Clinical trial NCT02543944: Improving Treatment Outcomes for Prescription Opioid Dependence
Official title: Improving Treatment Outcomes for Prescription Opioid Dependence
Acronym: GBN
Sponsor: University of Arkansas (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 117.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-02-29
Primary completion date: 2021-05-25
Completion date: 2021-05-31
Clinical trial NCT02497638: LIpitor and biGuanide to Androgen Delay Trial
Official title: A Randomized, Double Blind, Trial of Metformin and Atorvastatin in Delaying Androgen Deprivation Therapy Among Men With Rising PSA Following Radical Prostatectomy or Radiotherapy: The LIGAND (LIpitor and biGuanide to Androgen Delay) Trial
Acronym: LIGAND
Sponsor: University Health Network, Toronto (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Drug intervention no longer relevant for the proposed population
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-31
Primary completion date: 2021-12-31
Completion date: 2022-12-31
Clinical trial NCT05559905: Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)
Official title: A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-4482 in Healthy Participants Inoculated With Experimental Respiratory Syncytial Virus
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 116.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-11-02
Primary completion date: 2023-04-18
Completion date: 2023-06-08
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04193904: A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer
Official title: A Safety and Preliminary Efficacy Study of the Oral Live Biotherapeutic MRx0518 With Hypofractionated Preoperative Radiation for Resectable Pancreatic Cancer
Sponsor: 4D pharma plc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor insolvency
Enrollment: 13.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-20
Primary completion date: 2023-05-08
Completion date: 2023-05-08
Plan to share individual participant data: NO
Clinical trial NCT02686177: Effect of GLP-1 on Angiogenesis
Official title: Effect of GLP-1 on Angiogenesis, Angiosafe Type 2 Diabetes Study 1
Acronym: ANGIOSAFE 1
Sponsor: Assistance Publique - Hôpitaux de Paris (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-05-18
Primary completion date: 2017-08-08
Completion date: 2021-05-28
Plan to share individual participant data: NO
Clinical trial NCT03718650: Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer
Official title: Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer: Establishing the Radiomic/Pathologic Foundation of Heterogeneity
Sponsor: H. Lee Moffitt Cancer Center and Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-04-01
Primary completion date: 2022-04-01
Completion date: 2023-04-01
Clinical trial NCT01094977: Blood Loss and Transfusion Requirement in Infants Treated With Tranexamic Acid
Official title: Blood Loss and Transfusion Requirement in Infants Treated With Tranexamic Acid Undergoing Craniosynostosis Reconstruction: A Randomized Placebo-Controlled Double Blind Study of Low and High Dose Therapy
Sponsor: The Hospital for Sick Children (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: Inadequate funding
Enrollment: 90.0 (ESTIMATED)
Number of arms: 3.0
Start date: 2010-01-31
Primary completion date: 2020-01-31
Completion date: 2020-01-31
Clinical trial NCT02152943: Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
Official title: Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-Positive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming Resistance
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 37.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-07-17
Primary completion date: 2020-12-14
Completion date: 2020-12-14
Clinical trial NCT03320070: Acthar Gel in Participants With Pulmonary Sarcoidosis
Official title: A Multicenter, Randomized, Double Blind, Placebo Controlled Exploratory Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Pulmonary Sarcoidosis
Acronym: PULSAR
Sponsor: Mallinckrodt (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 55.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-21
Primary completion date: 2021-11-15
Completion date: 2021-11-15
Baseline population: The safety population included all randomized participants who received at least 1 dose of IMP.
Plan to share individual participant data: NO
Clinical trial NCT02750254: Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Official title: A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Toxicity. Only enrolled patients in phase I portion of trial.
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-06-27
Primary completion date: 2017-05-24
Completion date: 2020-10-14
Plan to share individual participant data: NO
Clinical trial NCT04301778: Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Official title: A Phase II Study of Durvalumab (MEDI4736) in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma.
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-08-24
Primary completion date: 2022-11-04
Completion date: 2024-02-06
Plan to share individual participant data: NO
Clinical trial NCT04134442: Improving Pain Management After Total Shoulder Replacement Using Bupivacaine Liposome
Official title: Improving Pain Management After Total Shoulder Replacement Using Bupivacaine Liposome
Sponsor: University of Massachusetts, Worcester (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: A new large meta-analysis was published. The results showed the likelihood that liposomal bupivacaine and nerve blocks no longer offer significant contribution. Decision was made to terminate the study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-09
Primary completion date: 2021-09-23
Completion date: 2021-09-23